AVXL Earnings & Financial Statements
Anavex Life Sciences Corp.
$1.33
-$0.03(-2.21%)
--
Overall
--
Value
--
Tech
--
Quality
Market Cap
--
Volume
626.21K
52W Range
$1.30 - $9.50
Target Price
--
AVXL earnings and financial statements: Anavex Life Sciences Corp.'s income statement, balance sheet and cash flow statement, annual and quarterly.
AVXL Annual Financial Statements
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating income | -$51.37M | -$52.88M | -$55.76M | -$50.99M | -$42.00M |
| EBITDA | -$51.05M | -$50.32M | -$54.02M | -$47.62M | -$37.64M |
| Net income | -$46.38M | -$43.00M | -$47.51M | -$47.98M | -$37.91M |
| EPS (diluted) | $-0.54 | $-0.52 | $-0.60 | - | $-0.54 |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total assets | $103.81M | $135.57M | $154.39M | $152.71M | $161.62M |
| Total liabilities | $8.95M | $15.30M | $12.53M | $10.21M | $10.80M |
| Shareholders’ equity | $94.87M | $120.26M | $141.85M | $142.49M | $150.82M |
| Cash and equivalents | $102.58M | $132.19M | $151.02M | $149.16M | $152.11M |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating cash flow | -$39.04M | -$30.81M | -$27.79M | -$24.24M | -$30.38M |
| Free cash flow | -$39.04M | -$30.81M | -$27.79M | -$24.24M | -$30.38M |
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | AVXL | $1.33 | -2.2% | 626.21K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Anavex Life Sciences Corp. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW